Synt001 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004055-37-ES (EUCTR) | 06/05/2020 | 10/05/2020 | ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | WAIHA MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: ALXN1830 INN or Proposed INN: ORILANOLIMAB Other descriptive name: SYNT001 | Alexion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | United States;Taiwan;Spain;Russian Federation;Italy;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Korea, Republic of | ||
| 2 | NCT03075878 (ClinicalTrials.gov) | January 10, 2018 | 3/3/2017 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA) | Warm Autoimmune Hemolytic Anemia | Drug: ALXN1830 | Alexion Pharmaceuticals | NULL | Terminated | 18 Years | N/A | All | 8 | Phase 1;Phase 2 | United States;Jordan |